Efferon NEO, a pediatric sepsis device, receives CE mark and expands international use

New Device for Pediatric Sepsis

Efferon, a startup selected for TechCrunch Disrupt 2026’s Startup Battlefield 200, has developed Efferon NEO, a medical device designed to treat pediatric sepsis. Sepsis is a significant cause of childhood mortality, affecting approximately 3 million children under five annually. The device aims to reduce organ failure rates and accelerate recovery in children by filtering blood to remove toxins and cytokines.

Multimodal Blood Purification

Efferon NEO functions by absorbing both endotoxins and cytokines, which are compared to the 'flame' and 'smoke' of an immune system overreaction during sepsis. Unlike other devices, Efferon NEO can absorb both simultaneously. The device is specifically engineered for children due to their lower circulating blood volume, a critical physiological difference requiring specialized medical solutions.

Regulatory Approval and Global Reach

In April, Efferon NEO received a CE mark, which is Europe's equivalent to FDA approval. This makes it the first multimodal blood purification device specifically designed for pediatric sepsis. The device is currently deployed in intensive care units across 30 countries, including European hospitals, Saudi Arabia, and Thailand. Efferon is preparing to file for FDA approval in the United States.

Company Background and Future Outlook

The technology behind Efferon was originally developed by scientists at Moscow State University. Dima Romashin joined as CEO to commercialize the technology. The company projects to achieve $2 million in annualized revenue by the end of 2026. While not growing at the pace of AI startups, Efferon measures its success by the impact on children's lives.